SPONSOR
Tianjin Medical University Cancer Institute and Hospital
Total Trials
10
Recruiting
10
Phases
Phase 2, Phase 3, Phase 1
Conditions studied: Mesothelin Positive TumorsChemotherapy-Induced Nausea and Vomiting (CINV)Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast CancerCANCERBRAEST CANCERLate FrontlinePrimary Liver CancerBreast CancerNeoadjuvant TherapyImmune Checkpoint Inhibitors
Tianjin Medical University Cancer Institute and Hospital is a clinical research sponsor with 10 registered studies on ClinicalTrials.gov, of which 10 are actively recruiting participants. Research covers conditions including Mesothelin Positive Tumors, Chemotherapy-Induced Nausea and Vomiting (CINV), Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer, CANCER.
The trial portfolio spans Phase 2, Phase 3, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Tianjin Medical University Cancer Institute and Hospital
How many clinical trials has Tianjin Medical University Cancer Institute and Hospital sponsored?
ClinicalMetric currently tracks 10 clinical trials sponsored by Tianjin Medical University Cancer Institute and Hospital, of which 10 are actively recruiting participants. These trials cover conditions including Mesothelin Positive Tumors, Chemotherapy-Induced Nausea and Vomiting (CINV), Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Tianjin Medical University Cancer Institute and Hospital research focus on?
Tianjin Medical University Cancer Institute and Hospital clinical trials span Mesothelin Positive Tumors, Chemotherapy-Induced Nausea and Vomiting (CINV), Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer, CANCER, BRAEST CANCER, and additional conditions. The research pipeline includes Phase 2, Phase 3, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Tianjin Medical University Cancer Institute and Hospital clinical trial?
To participate in a Tianjin Medical University Cancer Institute and Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Tianjin Medical University Cancer Institute and Hospital trials with current recruitment status updated daily.
Clinical Trials by Tianjin Medical University Cancer Institute and Hospital
NCT06717022
Recruiting
A Clinical Study of CHT102 in Mesothelin Positive Advanced Solid Tumors
Mesothelin Positive Tumors
NCT07726433 Phase 2
Recruiting
Fosrolapitant Combined With Palonosetron to Prevent Trastuzumab Rezetecan Related CINV
Chemotherapy-Induced Nausea and Vomiting (CINV)
NCT06878625 Phase 2
Recruiting
A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer
Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer
NCT06495515 Phase 2
Recruiting
Dalpiciclib Plus Toremifene for First-line Advanced HR Positive and HER2 Negative Breast Cancer
CANCER
NCT06766643 Phase 2
Recruiting
Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver Cancer
Primary Liver Cancer
NCT07372079 Phase 2
Recruiting
Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy
Breast Cancer
NCT07092696 Phase 2
Recruiting
Induction Immunotherapy Combined With Chemotherapy Followed by Concurrent Chemoradiotherap and Immunotherapy for Cervical Cancer
Cervical Cancer
NCT07632118 Phase 3
Recruiting
Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery
Pancreatic Cancer
NCT07351903 Phase 1
Recruiting
A Single-arm, Open-label Study of GK01 in Combination With or Without Chemotherapy for the Adjuvant Treatment of Solid Tumors
Solid Tumors
NCT07691619 Phase 2
Recruiting
Hypofractionated Radiotherapy After Complete Resection for Stage II/III Thymic Epithelial Tumors
Thymic Epithelial Tumor
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology